Object. Individuals who develop a unilateral vestibular schwannoma (VS) and other neurogenic tumors are at high risk of having the inherited condition neurofibromatosis Type 2 (NF2). The risk of bilateral disease and transmission risk to offspring are important in surgical planning and counseling. The authors have attempted to resolve these risks.
ESTIBULAR schwannomas are benign tumors of the nerve sheath usually affecting the superior branch of the vestibular portion of cranial nerve VIII. 7 With improved modern imaging with Gd-enhanced MR imaging, the incidence of VS has increased to 1 in 80,000 per annum, suggesting a lifetime risk in the general population of ~ 1 in 1000. 7, 13 Between 5 and 7.5% of VSs are due to the inherited autosomal dominant condition NF2. 7 Neurofibromatosis Type 2 affects ~ 1 in every 25-30,000 live births and usually presents as bilateral VS at first presentation. 7 Nonetheless, a significant minority presents with other tumor disease such as meningioma, and between 10 and 25% of VSs are diagnosed initially unilaterally. 5, 6 In particular, patients may present with a unilateral VS and other schwannomas or meningiomas. 5, 6, 12 According to the most sensitive criteria (Manchester criteria), the diagnosis for an individual with two NF2-related tumors in addition to a unilateral VS is NF2. 2 However, many of these patients have a partial "mosaic" form of the disease, in which the genetic mutation occurs after conception and only affects a proportion of cells in the individual. 9, 10 The chances that this individual will eventually develop bilateral VS or will have children who are affected by the disease has yet to be fully defined, although a recent paper has shown that contralateral risk approaches 30%, and that none of the children of the 44 adults identified had definitively developed NF2. 1 Our experience seemed somewhat different, and we therefore analyzed our dataset of Ͼ 700 patients with NF2 to determine whether this was actually the case.
Clinical Material and Methods

Analysis of NF2 Database
We undertook an updated analysis of our NF2 database, which now includes 704 patients with NF2. Patients are either referred to us for mutation analysis or have been seen as part of our specialist service. Family trees are drawn to identify deceased individuals who had the disease, and information from hospital records is sought to verify their diagnosis. All patients on the database fulfill Manchester criteria or have an NF2 germline or proven mosaic mutation (identical mutation in 2 separate tumors). Age at onset or laterality at presentation were examined. Patients who presented with a unilateral VS, in whom no contralateral VS was identified on neuroimaging but in whom other NF2 tumors were present, and those in whom tumors had been What are the implications in individuals with unilateral vestibular schwannoma and other neurogenic tumors? removed or had occurred subsequently before the presence of a contralateral VS were identified. Patterns of presentation and tumors identified were noted. The probability of developing a contralateral VS was estimated using a Kaplan-Meier analysis.
Mutation Analysis
Mutation analysis was conducted on DNA extracted from blood lymphocytes and, where possible, tumor material (as previously described) 11, 14 by screening all 17 exons of the NF2 gene. This used either single-strand conformational polymorphism or, since 2000, direct sequencing of all exons. Since 2000, we have also used an approach to detect whole-exon duplications and deletions; 14 more recently this has been performed using the P044 MLPA (MRCHolland).
Offspring Risk
The risk to offspring was assessed by analyzing available pedigrees.
Results
Analysis of NF2 Database
Of the 704 patients in the NF2 database, 277 have been seen by at least 1 of the authors (D.G.E.), and 48 deceased affected relatives have been identified from family trees. Age at onset and laterality at presentation were not available for 44 patients, and 49 (7%) had yet to develop VS (18 of these were presymptomatic diagnoses based on genetic testing and only 12 of the 49 were Ͼ 20 years of age). Sixteen patients did not have information on the presence of VS, of whom 6 were inferred to be deceased carriers of NF2. Another 48 patients with bilateral disease did not have information on laterality at presentation. Of the remainder, 142 (24%) of 590 patients initially presented with a unilateral VS. The proportion of those seen by ourselves was very similar 65 (23.5%) of 277. Thirty of these patients were asymptomatic children or young adults undergoing a first screening. However, 107 of 142 were known to be the first patient in the family affected with NF2. Further analysis concentrated on these 107 patients.
Eleven patients presented with an apparently unilateral sporadic VS, and between 1 and 17 years later they developed a subsequent contralateral tumor that had not been visible on the initial MR image, with no other tumor being identified in the interim. This left a main study group of 96 patients who had a unilateral VS and other NF2 tumors before developing bilateral tumors, or who fulfilled Manchester criteria by having at least 2 additional NF2-related tumors. In Table 1 we have detailed the tumor development in 63 patients presenting at Ͻ 40 years of age. In the main group, 57 (59%) of 96 patients were female and 63 (66%) of 96 had cranial meningiomas in addition to unilateral VS. Forty-three (68%) of the 63 patients with meningioma were female. Thus, meningioma cases accounted for an excess of females in the study group. Fifty-seven (59%) of 96 have yet to develop a contralateral VS. This dropped to 22 (48%) of 46 in those presenting at Ͻ 30 years of age and 5 (28%) of 18 in those Յ 18 years of age.
In 29 patients, their initial unilateral VS was diagnosed prior to 1990, without high-resolution thin-slice MR imaging. Twelve of these 29 have yet to develop contralateral tumors. In 10 patients, both the initial and contralateral tumor were diagnosed earlier than 1990, with the contralateral tumor diagnosed 1-22 years later (median 6 years later) than the initial one. In 4 of these patients Ͻ 5 years had elapsed from the initial diagnosis, and they may have had a contralateral tumor that would have been detectable with modern imaging. Two of these (50%) were Ͻ 18 years old at diagnosis and had a mutation detectable in blood but did not have children. The remaining 7 patients had undergone imaging studies in the modern MR imaging era before developing contralateral tumors 4-13 years after unilateral diagnosis. Mutation testing in peripheral lymphocytes was possible in 92 of 96 patients. Mutations were detectable in blood in 25 (27%) of 92, but there was a clear effect of age at diagnosis. Thirteen (76%) of 17 patients presenting with unilateral VS who were Յ 18 years old had a mutation detectable in blood (1 mosaic) and another patient was shown to be mosaic with a mutation only detectable in tumors. Only 8 of 23 (35%; 2 patients were not tested) of those presenting with unilateral VS between the ages of 19 and 29 years had a mutation detectable in blood (3 mosaic), and 3 more mosaic mutations were identified by tumor analysis. In the age group between 30 and 39 years, only 2 (11%) of 18 had a mutation in blood (1 mosaic; 6 more mosaics were identified on tumor analysis). Of the remaining 34 patients with a diagnosis of unilateral VS who were Ն 40 years of age, only 1 (3%) had a mutation detectable in blood (c.676-7 T Ͼ G; a mutation known to cause mild disease); 7 more patients had a mutation identified from tumor. Altogether, 25 (27%) of 94 had a mutation detectable in blood (5 mosaic) and another 18 were identified as mosaic on tumor analysis or analysis in offspring. In no patient was NF2 excluded by identifying different mutations in 2 separate tumors. There was no clear effect of loss of sensitivity of mutation testing in the earlier era. Fifteen (44%) of 34 were identified prior to 2000 (5 of 8 in tumor), whereas 27 (47%) of 58 were identified in the more recent era (13 of 15 in tumor).
Of Ͼ 60 children born to the cohort in total, there were 7 affected children born to 5 parents among the 96 patients. In 2 of these patients, a mosaic mutation was detectable in blood (Cases 41 and 63), and these have been previously described. 3, 11 In 1 patient (Record No. 149/101; not shown in Table 1 ), who presented at the age of 56 years with unilateral VS and 6 cranial meningiomas (4 spinal tumors were also found on neuroimaging), an exon 7 duplication was identified in her affected son. This was not present on MLPA analysis in her own blood sample, and we have to assume that she had a mosaic mutation for the duplication. In another patient (Case 18, Table 1 ), a splice site mutation (nonmosaic) was detected in blood; this was inherited by his affected daughter. The fifth patient (Case 33), in whom a unilateral VS was diagnosed at the age of 24 years, was noted to have a cutaneous tumor. His son has developed classic NF2, but it has not been possible to obtain a blood sample from the father.
Kaplan-Meier analysis is presented in Figs. 1 and 2 , which show the total dataset and ages split at 18 years.
We also analyzed the proportion of patients with sporadic NF2 in whom a mutation was detectable in blood by lat- (47) c.586CϾT; p.Arg196X mosaic ‡ * CM = cranial meningioma; CrSX, CrSXII = 10th, 12th cranial nerve schwannoma; CS = cutaneous schwannoma; Ep = ependymoma; NA = not applicable; RH = retinal hamartoma; Sp = spinal tumor; SpS = spinal schwannoma.
† Mosaic mutation found only in tumor and confirmed in a second tumor or different areas of a multifocal lesion. Tumor analysis has not been possible in the other patients in whom a germline mutation has not been found.
‡ Two children with NF2 led to the diagnosis of unilateral VS in their father; the mutation in the daughters was present at a low level in blood. erality at presentation. In 137 (63%) of 217 who presented with bilateral tumors, there was a detectable mutation in blood (19 were mosaic), and 13 more mosaic mutations were detected only in tumor. Only 30 (30%) of 101 patients presenting initially with a unilateral VS had a mutation detectable in blood (4 mosaic), and 19 more (19%) were identified as mosaic from tumor analysis. When tumor analysis was undertaken it was possible to identify the mosaic mutation in 34 (74%) of 46 cases.
Discussion
We have shown that patients who develop other NF2-related tumors in addition to a unilateral VS are likely to have at least a mosaic form of NF2. If they develop at least 2 non-VS tumors then it is extremely unlikely that this is a chance occurrence, and the diagnosis should be NF2. 2 We agree with Aghi et al. 1 that this has important implications for patient management and genetic counseling. Patients with this presentation are best served by being referred to a multidisciplinary NF2 clinic. 4 At the time of any surgery, at least part of any tumor removed should be fresh-frozen to allow subsequent molecular analysis. Management of the unilateral VS should take into account the risk of a future contralateral tumor and therefore possible total deafness.
Aghi et al. 1 have recently reported on their experience of this presentation. They describe it as a "unique phenotype." We would disagree with this and argue that it is merely part of the spectrum of NF2, from the classic form of the disease with a mutation inherited in the zygote and present in all cells to a mosaic form with an often more asymmetrical presentation. Our cohort differs from that of Aghi et al. in 2 main ways. First, they excluded patients who had not had at least 1 skull base MR image (axial postcontrast slice thickness of 3 mm) that was negative for contralateral tumor after the age of 18 years. In our analysis we were not able to review all radiological imaging, and it is possible that some contralateral tumors were present as tiny occult lesions. Many of the patients were followed over decades, but it would have been a lot more difficult to identify a small, 3-mm VS in a patient who had undergone MR imaging in the mid-1980s, or even in the late 1980s, as opposed to beyond 2000, with the high-resolution systems that have become available. We have broken down the series based on year at initial diagnosis and found that perhaps 4 patients who went on to develop bilateral disease after an initial unilateral diagnosis prior to 1990 may have had a contralateral tumor that would have been detectable if they had undergone modern imaging with thin slices at initial assessment. Even excluding these 4 patients does not materially affect the overall results. Therefore, our current report reflects the reality of imaging in many centers, particularly as half of all patients were reviewed by the authors. The similar frequency of asymmetrical presentation in both groups does not suggest any bias in ascertainment. Clearly, in all patients in whom NF2 is suspected, a goodquality MR image of both internal auditory meati with at least 3-mm cuts or sections should be obtained. 1 By including patients of all ages we have been able to address the issue of what proportion of cases with germline mutations have an asymmetrical presentation. Furthermore, our mutation detection methods were more sensitive than those used by Aghi et al., 1 because we also used MLPA. Our data show that a high proportion of patients presenting with a unilateral VS and other NF2 related-tumors at Յ 18 years of age have germline NF2 mutations (13 [76%] of 17). From the age of Ն 19 years, the proportion of people with germline mutations fell steeply (7 [9.3%] of 75). By including these cases our data show a much higher risk of contralateral VS than shown by Aghi et al. They showed a 28.8% risk 25-40 years after initial presentation. We have divided our cohort by age and not surprisingly found a much higher frequency in those presenting at Յ 18 years of age. However, even in the remainder of our patients, the 20-year risk of contralateral disease was 48%. A further reason for this may be that we included all patients with an initial unilateral presentation. Although Aghi et al. do not state this as a study criterion, their data suggest that they excluded all cases with a known germline mutation. Again, we argue that our approach provides the most useful clinical data because it represents the clinical presentation of all cases.
Both our study and that of Aghi et al. had an excess of female patients. We agree with their hypothesis that perhaps mosaic inactivation is more frequent in meningioma precursor cells. It is already known that meningiomas are more frequent in female patients with NF2.
An attempt can be made to calculate offspring risk in individuals with a unilateral VS and other neurogenic tumors. More than 10% of children born to our series of patients have developed NF2, and others may yet develop the disease. Nonetheless, the risk will still be less than the usual 50% due to the high level of mosaicism. In the youngest age group (Ͻ 18 years), the risk will be ~ 40% prior to mutation testing. This will reduce to 20% in the 19-29-year-old group and ~ 10% for those diagnosed at Ͼ 30 years. If a mutation is found in blood lymphocytes, the risk will be 50% unless the patient is mosaic, in which case risks will depend on the proportion of cells affected. If mutation analysis is negative in blood, the offspring risk will drop to Ͻ 8% regardless of age at onset. 8 If a point mutation is found in tumors but not blood, this risk decreases even further to Ͻ 5%. 8 
Conclusions
When a patient with a unilateral VS is found to have Ն 1 other NF2-related tumors, the consideration that this is at least mosaic NF2 is important. The increasing awareness of mosaic NF2 reflects improved neuroimaging techniques and mutation detection techniques for NF2 analysis in blood on paired tumor samples.
